| PVA Removal from Official List - Monday, 7 May 2018 |
| 04/05/18 | | 221.8KB | Share |
|
| PVA Suspension from Official Quotation |
| 30/04/18 | PRICE SENSITIVE | 222.09KB | Share |
|
| PVA Preliminary Proxy |
| 30/04/18 | | 297.74KB | Share |
|
| PVA Reinstatement to Official Quotation |
| 26/04/18 | PRICE SENSITIVE | 221.52KB | Share |
|
| PVA Response to ASX Price and Volume Query |
| 26/04/18 | PRICE SENSITIVE | 985.68KB | Share |
|
| PVA Suspension from Official Quotation |
| 26/04/18 | PRICE SENSITIVE | 221.46KB | Share |
|
| PVA EyePoint Patent Allowance |
| 13/04/18 | PRICE SENSITIVE | 144.76KB | Share |
|
| PVA Approval to Delist |
| 04/04/18 | | 576.29KB | Share |
|
| PVA Form 8-K |
| 03/04/18 | | 66.07KB | Share |
|
| PVA ASX Delisting |
| 29/03/18 | | 116.89KB | Share |
|
| PVA pSivida Announces Acquisition of Icon |
| 29/03/18 | PRICE SENSITIVE | 168.11KB | Share |
|
| PVA Nancy Lerker Form 4 |
| 22/03/18 | | 100.83KB | Share |
|
| PVA Len Ross Form 4 |
| 22/03/18 | | 97.9KB | Share |
|
| PVA Dario Paggiarino Form 4 |
| 22/03/18 | | 135.42KB | Share |
|
| PVA Deb Jorn Resignation |
| 22/03/18 | | 33.54KB | Share |
|
| PVA pSivida Announces FDA Acceptance For Filing of New Drug Appl |
| 20/03/18 | PRICE SENSITIVE | 66.22KB | Share |
|
| PVA Appendix 3B |
| 20/03/18 | | 824.28KB | Share |
|
| PVA pSivida Corp Dec 2017 Form 10-Q |
| 09/02/18 | PRICE SENSITIVE | 634.37KB | Share |
|
| PVA Form 8-K Earnings Release for Q2 FY 2018 |
| 09/02/18 | PRICE SENSITIVE | 72.28KB | Share |
|
| PVA Appendix 3B - January 2018 |
| 02/02/18 | | 375.33KB | Share |
|
| PVA Corporate Governance Report - January 2018 |
| 30/01/18 | | 325.71KB | Share |
|
| PVA Appendix 4G - January 2018 |
| 30/01/18 | | 474.68KB | Share |
|
| PVA pSivida Submits New Drug Application (NDA) for Durasert |
| 10/01/18 | PRICE SENSITIVE | 316.47KB | Share |
|
| PVA Appendix 3B - December 2017 |
| 10/01/18 | | 369.42KB | Share |
|
| PVA pSivida Granted Waiver by the FDA for NDA Fee |
| 05/01/18 | PRICE SENSITIVE | 245.5KB | Share |
|
| PVA Form 4 (Leonard Ross) |
| 28/12/17 | | 134.49KB | Share |
|
| PVA Appendix 3Y - Rogers |
| 27/12/17 | | 123.14KB | Share |
|
| PVA Appendix 3Y - Peterson |
| 27/12/17 | | 73.08KB | Share |
|
| PVA Appendix 3Y - Mazzo |
| 27/12/17 | | 123.48KB | Share |
|
| PVA Appendix 3Y - Lurker |
| 27/12/17 | | 94.47KB | Share |
|
| PVA Appendix 3Y - Godshall |
| 27/12/17 | | 104.98KB | Share |
|
| PVA Appendix 3Y - Duker |
| 27/12/17 | | 79.92KB | Share |
|
| PVA Appendix 3Y - Barry |
| 27/12/17 | | 93.72KB | Share |
|
| PVA Form 4 (Michael Rogers) |
| 20/12/17 | | 137.35KB | Share |
|
| PVA Form 4 (Nancy Lurker) |
| 20/12/17 | | 102.6KB | Share |
|
| PVA Form 4 (James Barry) |
| 20/12/17 | | 136.62KB | Share |
|
| PVA Form 4 (Jay Duker) |
| 20/12/17 | | 102.03KB | Share |
|
| PVA Form 4 (Kristine Peterson) |
| 20/12/17 | | 99.46KB | Share |
|
| PVA Form 4 (Douglas Godshall) |
| 20/12/17 | | 103.25KB | Share |
|
| PVA Form 4 (David Mazzo) |
| 20/12/17 | | 103.25KB | Share |
|
| PVA Form 8-K (Annual Stockholder Meeting Results) |
| 20/12/17 | | 41.07KB | Share |
|
| PVA HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis |
| 15/12/17 | PRICE SENSITIVE | 526.78KB | Share |
|
| PVA Appendix 3B - November 2017 |
| 05/12/17 | | 365.06KB | Share |
|
| PVA Form 14A (Definitive Proxy Statement) |
| 15/11/17 | | 411.14KB | Share |
|
| PVA Form 10-Q - September 30, 2017 |
| 14/11/17 | PRICE SENSITIVE | 173.5KB | Share |
|
| PVA Form 8-K (Q1 FY 2018 Earnings Release) |
| 08/11/17 | PRICE SENSITIVE | 70.92KB | Share |
|
| PVA Appendix 3B - October 2017 |
| 07/11/17 | | 375.39KB | Share |
|
| PVA Schedule 14A (Preliminary Proxy Statement) |
| 06/11/17 | | 624.84KB | Share |
|
| PVA Form 10 - K/A |
| 01/11/17 | | 270.92KB | Share |
|
| PVA pSivida and Nicox Enter Strategic Collaboration Agreement |
| 12/10/17 | PRICE SENSITIVE | 332.79KB | Share |
|
| PVA SEC Grant of Confidential Treatment (Exhibit 10.23 Form 10K) |
| 12/10/17 | | 8.89KB | Share |
|
| PVA Appendix 3B - September 2017 |
| 04/10/17 | | 377.67KB | Share |
|
| PVA pSivida to Present at the Ladenburg Thalmann 2017 Healthcare |
| 25/09/17 | | 432.85KB | Share |
|
| PVA Prospectus Supplement |
| 21/09/17 | PRICE SENSITIVE | 39.96KB | Share |
|
| PVA pSivida Corp FY 2017 Form 10-K as filed for ASX |
| 14/09/17 | PRICE SENSITIVE | 1.14MB | Share |
|
| PVA Form 8-K Earnings Release |
| 13/09/17 | PRICE SENSITIVE | 72.43KB | Share |
|
| PVA Appendix 3B - August 2017 |
| 07/09/17 | | 369.92KB | Share |
|
| PVA Appendix 3B - July 2017 |
| 03/08/17 | | 371.76KB | Share |
|
| PVA Appendix 3B for June 2017 |
| 12/07/17 | | 373.4KB | Share |
|
| PVA EMEA Out License and Amended Global Collaboration Agreement |
| 11/07/17 | PRICE SENSITIVE | 66.75KB | Share |
|
| PVA Form 8K, Appt. of New BoD, Adoption of ST Incentive Plan |
| 03/07/17 | | 71.46KB | Share |
|
| PVA Appendix 3X (Kristine Peterson) |
| 03/07/17 | | 191.23KB | Share |
|
| PVA SEC Form 4 (Debora Jorn) |
| 30/06/17 | | 143.75KB | Share |
|
| PVA SEC Form 4 (Leonard Ross) |
| 30/06/17 | | 144.14KB | Share |
|
| PVA SEC Form 4 (Dario Paggiarino) |
| 30/06/17 | | 143.73KB | Share |
|
| PVA Results of Special Meeting of Shareholders |
| 30/06/17 | | 37.21KB | Share |
|
| PVA Disclosure Document |
| 26/06/17 | PRICE SENSITIVE | 56.01KB | Share |
|
| PVA Disclosure Document |
| 16/06/17 | PRICE SENSITIVE | | Share |
|
| PVA Form 4 - Nancy Lurker |
| 16/06/17 | | | Share |
|
| PVA Appendix 3B |
| 05/06/17 | | 374.93KB | Share |
|
| PVA Definitive Proxy Statement (DEF 14A) |
| 17/05/17 | | 277.22KB | Share |
|
| PVA Disclosure Document |
| 10/05/17 | PRICE SENSITIVE | 193.2KB | Share |
|
| PVA Disclosure Document |
| 09/05/17 | PRICE SENSITIVE | 381.8KB | Share |
|
| PVA Disclosure Document |
| 05/05/17 | | 43.44KB | Share |
|
| PVA Disclosure Document |
| 05/05/17 | PRICE SENSITIVE | 76.17KB | Share |
|
| PVA Disclosure Document |
| 05/05/17 | | 278.55KB | Share |
|
| PVA Appendix 3B |
| 05/05/17 | | 369.62KB | Share |
|
| PVA pSivida Corp. To Report Third Quarter Fiscal Year 2017 Finan |
| 21/04/17 | | 325.33KB | Share |
|
| PVA Appendix 3B |
| 06/04/17 | | 337.71KB | Share |
|
| PVA Abstract on pSivida's Treatment of Posterior Segment Uveitis |
| 16/03/17 | PRICE SENSITIVE | 528.59KB | Share |
|
| PVA Form 8K |
| 07/03/17 | PRICE SENSITIVE | 102.28KB | Share |
|
| PVA Appendix 3B |
| 03/03/17 | | 336.55KB | Share |
|
| PVA Form S-8 Registration Statement |
| 23/02/17 | | 83.65KB | Share |
|
| PVA pSivida to Present at the 2017 BIO CEO & Investor Conference |
| 13/02/17 | | 318.38KB | Share |
|
| PVA Disclosure Document |
| 10/02/17 | | 799.44KB | Share |
|
| PVA Disclosure Document |
| 09/02/17 | PRICE SENSITIVE | 349.17KB | Share |
|
| PVA Disclosure Document |
| 09/02/17 | PRICE SENSITIVE | 298.06KB | Share |
|
| PVA Disclosure Document |
| 08/02/17 | PRICE SENSITIVE | 189.32KB | Share |
|
| PVA Appendix 3B |
| 06/02/17 | | 339.32KB | Share |
|
| PVA Disclosure Document |
| 03/02/17 | | 299.03KB | Share |
|
| PVA Disclosure Document |
| 27/01/17 | | 446.73KB | Share |
|
| PVA Appendix 3B |
| 06/01/17 | | 337.69KB | Share |
|
| PVA Disclosure Document |
| 03/01/17 | PRICE SENSITIVE | 130.31KB | Share |
|
| PVA Disclosure Document |
| 28/12/16 | | 169.07KB | Share |
|
| PVA Disclosure Document |
| 21/12/16 | | 150.85KB | Share |
|
| PVA Form 8-K |
| 19/12/16 | | 128.04KB | Share |
|
| PVA Change of Director's Interest Notice |
| 15/12/16 | | 96.35KB | Share |
|
| PVA Change of Director's Interest Notice |
| 15/12/16 | | 97.21KB | Share |
|
| PVA Change of Director's Interest Notice |
| 15/12/16 | | 85.61KB | Share |
|
| PVA Change of Director's Interest Notice |
| 15/12/16 | | 65.32KB | Share |
|
